5 Key Takeaways

• 1

  The FDA has approved Encelto, the first treatment for Macular Telangiectasia type 2 (MacTel), a degenerative retinal disease.

• 2

  Encelto is an ocular insert that delivers sustained doses of ciliary neurotrophic factor (CNTF) to the retina.

• 3

  Clinical trials demonstrated that Encelto significantly slowed macular photoreceptor loss over 24 months.

• 4

  MacTel affects approximately 0.1% of the U.S. population, equating to around 250,000 individuals.

• 5

  Encelto is expected to be available in the United States by June 2025, marking a significant advancement for MacTel patients.